Will the new SGLT2 inhibitor empagliflozin help us reduce the risk of hypoglycemia?

Česká verzia

Authors: Terezie Pelikánová
Authors place of work: Centrum diabetologie IKEM Praha, přednostka prof. MUDr. Terezie Pelikánová, DrSc.
Published in the journal: Vnitř Lék 2014; 60(12): 1102-1108
Category: Review

Summary

The treatment of patients with type 2 diabetes is typically accompanied by hypoglycemia, if insulin or derivatives of sulfonylurea are used within the treatment. Apart from the fact that hypoglycemias are the major obstacle to achieving the desirable compensation of diabetes, hypoglycemia also has a number of serious clinical consequences. A long term serious hypoglycemia may lead to a sudden death, heart attack or irreversible brain damage. Clinically significant are also the light or asymptomatic hypoglycemias which in a considerably negative way affect the patient's quality of life. The use of modern technologies in continuous monitoring of glycemias has shown that the occurrence of asymptomatic hypoglycemias is much higher than we anticipated and that they largely involve nocturnal hypoglycemia. Hypoglycemia is associated with an increased level of depression, anxiety, dissatisfaction with the treatment and with a greater number of physician office visits. Nocturnal hypoglycemia has a negative impact on the quality of sleep, it may impair cognitive functions and performance efficiency next day. The prevention of hypoglycemia is therefore one of the basic goals of diabetes treatment and the low risk of hypoglycemia is among the main requirements that we place on the newly developed antidiabetic drugs. The negligible risk of hypoglycemia, which is comparable to placebo both in monotherapy and in most combinations with the antidiabetic drugs available today, is evidenced by the data from the studies undertaken with empagliflozin. It shows that the low risk of hypoglycemia is one of the benefits of gliflozins, the new group of medications with a unique mechanism of effect which has quite recently appeared on our market.

Key words:
diabetes mellitus type 2 – gliflozins – hypoglycemia

Zdroje

1. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28(5): 1245–1249.

2. Oyer DS. The science of hypoglycemia in patients with diabetes. Curr Diabetes Rev 2013; 9(3): 195–208.

3. Pelikánová T, Bartoš V. Praktická diabetologie. 5th ed. Maxdorf: Praha 2012. ISBN 978–80–7345–244–5.

4. Škrha J. Hypoglykemie. Od patofyziologie ke klinické praxi. Maxdorf: Praha 2013. ISBN 978–80–7345–319–0.

5. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560–2572.

6. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2559.

7. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129–139.

8. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33(6): 1389–1394.

9. Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 2014; 63(7): 2188–2195.

10. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012; 35(9): 1814–1816.

11. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 2010; 16(2): 244–248.

12. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111(7): 405–414.

13. Johnston SS, Conner C, Aagren M et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34(5): 1164–1170.

14. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909. Dostupné z DOI: <http://doi: 10.1136/bmj.b4909>.

15. Asvold BO, Sand T, Hestad K et al. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: a 16-year follow-up study. Diabetes Care 2010; 33(9): 1945–1947.

16. Jacobson AM, Musen G, Ryan CM et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356(18): 1842–1852.

17. Bruce DG, Davis WA, Casey GP et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia 2009; 52(9): 1808–1815.

18. Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301(15): 1565–1572.

19. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 91(3): 363–370.

20. Jones TW, Porter P, Sherwin RS et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338(23): 1657–1662.

21. Brod M, Christensen T, Thomsen TL et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2012; 14(5): 665–671.

22. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012; 15(1): 77–86.

23. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013; 369(4): 362–372.

24. Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22(6): 749–755.

25. Miller CD, Phillips LS, Ziemer DC et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161(13): 1653–1659.

26. Chico A, Vidal-Rios P, Subira M et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003; 26(4): 1153–1157.

27. Weber KK, Lohmann T, Busch K et al. High frequency of unrecognized hypoglycaemias in patients with Type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2007; 115(8): 491–494.

28. Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007; 117(4): 868–870.

29. Bergenstal RM, Klonoff DC, Garg SK et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369(3): 224–232.

30. Saudek F. Transplantační léčba diabetu: příručka pro pacienty s diabetem a jejich blízké. Maxdorf: Praha 2010. ISBN 978–80–7345–222–3.

31. Roden M, Weng J, Eilbracht J et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1(3): 208–219.

32. Haring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37(6): 1650–1659.

33. Kovacs CS, Seshiah V, Swallow R et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16(2): 147–158.

34. Rosenstock J, Seman LJ, Jelaska A et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15(12): 1154–1160.

35. Rosenstock J, Jelaska A, Frappin G et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37(7): 1815–1823.

36. Haring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36(11): 3396–3404.

37. Rušavý Z. Nový SGLT2 inhibitor empagliflozin: moderní a bezpečná léčba diabetu. VnitřLék 2014; 60(11):926–930.